WRLD A.LIVE

23:002 reports

• New leukemia drug suppresses cancer-driving protein more strongly than existing treatments within one week Medical Xpress
• ASTRO updates guideline on shorter-course radiation therapy for localized prostate cancer | Newswise Newswise

22:003 reports

• Natalia Baran at LeukO 2026: The Next Breakthrough in CML May Be Life Without Treatment Oncodaily
• Breakthrough targeted therapy shows strong precision in treating chronic myeloid leukemia News-Medical
• Single-cell sequencing data shows how pancreatic cancer tumors evolve to resist therapy Drug Discovery News

21:00nothing heard

20:001 report

• Hidden bacterial compounds reveal potential cancer drug leads Drug Target Review

19:004 reports

• Scientists create 500 models to predict the risk of 20 types of cancer — News-Medical UA.NEWS
• Artificial intelligence allows detecting people at higher risk of cancer, according to a new international study. Demócrata
• Emad Shash: Why AI in Cancer Care Needs Both Vision and Clinical Judgment? Oncodaily
• Machine learning models predict common cancer risks using routine health data News-Medical

18:001 report

• Symbolic AI-driven "Digital Twins" predict personalised cancer treatments Open Access Government

17:00nothing heard

16:00nothing heard

15:00nothing heard

14:001 report

• Cryopreservation techniques for adult and pediatric glioblastoma organoids and their effects on stem cell self-renewal Nature

13:003 reports

• Cerebrospinal fluid liquid biopsy detects tumor DNA in complex brain cases News-Medical
• The Surprising Clues BMI May Miss in Head and Neck Cancer Medscape
• Exploring the potential of immunotherapy in early-stage triple-negative breast cancer Medical Xpress

12:001 report

• One antibody, three targets: New strategy against triple-negative breast cancer American Society for Biochemistry and Molecular Biology

11:00nothing heard

10:00nothing heard

09:002 reports

• New AI platform helps uncover promising cancer drug combinations UCLA Health
• Scientists discover hidden weaknesses in microtubules stabilized by a cancer drug Asia Research News |

08:002 reports

• Sac-TMT Improves PFS and OS, Is Under FDA Priority Review in Previously Treated Endometrial Cancer OncLive
• MRK: Positive Phase 3 results for sac-TMT and intismeran underpin a broad oncology pipeline TradingView

07:001 report

• Personalized cancer vaccine plus immunotherapy reduces melanoma recurrence after surgery Medical Xpress

06:008 reports

• New players provide hope in imatinib-resistant GIST FirstWord Pharma
• We are going to cure cancer. AI will help us do it Washington Times
• AI Gives Pathologists "Super Vision": A New Era in Cancer Detection Vocal
• Anna Geguchadze: How AI Is Reshaping Young Oncologists’ Daily Work? Oncodaily
• Running Toward a Cure: Reflections at “Next Conversations” The Johns Hopkins News-Letter
• Jame Abraham: Anbenitamab Shows Promising PFS Benefit in HER2+ Advanced Breast Cancer Oncodaily
• Results From a Phase III Clinical Study of Anbenitamab in Combination With Docetaxel for Injection for the First-Line Treatment of HER2-Positive Advanced Breast Cancer FirstWord Pharma
• Moderna CEO Confident Cancer Vaccines Will Work Beyond Melanoma Bloomberg.com

05:005 reports

• Moderna’s Rally May Have Run Out of Steam. Here’s What to Watch Next Investopedia
• Personalized mRNA Cancer Vaccine Cuts Melanoma Recurrence Risk by 42% in Phase 3 Trial XenoSpectrum
• Obesity in Young Adults Linked to Multiple Early Cancers MedPage Today
• Liver Metastases OS Not Tied to Surgical Method Used Medscape
• Silent bacterial genes yield potential leads for future cancer drugs Phys.org

04:002 reports

• Cryopreservation techniques for adult and pediatric glioblastoma organoids and their effects on stem cell self-renewal Nature
• Location of rare cancer impacts survival, study suggests Medical Xpress

03:004 reports

• Digital tumour models predicted treatment response in 74% of cases — News-Medical UA.NEWS
• Reduced-Frequency Immunotherapy Fails to Demonstrate Noninferiority in Advanced Cancer in Phase 3 MOIO Trial HMP Global Learning Network
• UCL scientists design symbolic AI digital twins to treat cancer News-Medical
• Sac-TMT Improves Survival vs Chemotherapy in Pretreated Endometrial Cancer CancerNetwork

02:0012 reports

• KEYNOTE-C93 Shows PFS Benefit With First-Line Pembrolizumab Monotherapy in dMMR Endometrial Cancer OncLive
• Six-Gene Score Could Improve Survival Predictions for Acute Myeloid Leukemia The Indian Practitioner
• Predicting Leukemia Survival May Be Aided by Six Gene Scoring System Genetic Engineering and Biotechnology News
• Smart probe makes aggressive breast cancer cells glow during surgery News-Medical
• MIT implant could stop deadly brain tumors from coming back ttownmedia.com
• Mount Sinai Medical Center Physician Leads Global Phase 3 Trial Showing Chemotherapy-Free Treatment Improves Outcomes for Women with dMMR Endometrial Cancer Morningstar
• Pembrolizumab Alone Exceeds Chemo in First-Line dMMR Endometrial Cancer Targeted Oncology
• Tumor Budding in Invasive Breast Carcinoma: Association With Histopathological Features and Hormone Receptor Status Cureus
• Merck drug extends survival in endometrial cancer trial, wins US priority review Reuters
• US shifts away from treating low-risk prostate cancer — News-Medical UA.NEWS
• Hossam Abdulkhalek: Dato-DXd in TNBC Brain Metastases - Practice-Changing or Practice-Generating? Oncodaily
• Datroway Shows Encouraging Results for Triple-Negative Breast Cancer That Has Spread to the Brain https://news.cancerconnect.com/

01:008 reports

• Merck's Sac-TMT Lowers Risk of Death 32% in Advanced Endometrial Cancer Trial marketscreener.com
• TroFuse-005 at ESMO 2026: Sacituzumab Tirumotecan Significantly Improves Overall Survival in Advanced Endometrial Cancer Oncodaily
• Implantable device uses ultrasound to improve drug delivery to the brain MIT News
• Brain Implant Could Prevent Glioblastoma Relapse with Ultrasound Drug Delivery Inside Precision Medicine
• Merck's therapy extends survival in hard-to-treat uterine cancer patients TradingView
• ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer BioSpace
• Merck Drug Boosts Survival From Hard-to-Treat Uterine Cancer Bloomberg.com
• AI could help identify people at higher risk of common cancers using routine health data Medical Xpress

00:006 reports

• ESMO 2026: Survival Gains and New Treatment Strategies in GI Cancers Targeted Oncology
• Next-Gen Drug Significantly Prevents Return of and Death From Endometrial Cancer NYU Langone Health
• Mount Sinai Medical Center Physician Leads Global Phase 3 Trial Showing Chemotherapy-Free Treatment Improves Outcomes for Women with dMMR Endometrial Cancer PR Newswire
• ESMO: In sac-TMT’s first global phase 3 win, Merck sees ‘pretty consistent’ data with China Fierce Pharma
• Beyond the cancer vaccine, how did Merck’s oncology pipeline do at ESMO? Endpoints News
• Next-Gen Drug Significantly Prevents Return of and Death From Endometrial Cancer – Company Announcement Financial Times